Scholars Central

Conference abstractPublished 14 Nov 2016

Omics data strategy, precision medicine and modern biotechnology revolution

Authors: Dongliang Ge

Nanjing BioSciKin Co. Ltd, China

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The biopharmaceutical industry has quickly entered an era when fast evolving multidisciplinary omics technologies, historical precision medicine initiatives and disruptive bioinformatics techniques synergistically start to provide pivotal and strategic support for new drug development. Unprecedented amount of data is being generated to help discover and develop new generations of medications. Using examples, this talk covers several of the most important bioinformatic considerations in this strategy which includes: How do we efficiently manage the massive amount of data at different levels of precision to ensure a seamless data flow? How do we annotate and present these data to make it more comprehensible and deliverable? How do we design and execute the new clinical trials more efficiently and improve the success rate? Where are we and where are we going in this new precision medicine era?

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Metabolomics:Open Access.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalMetabolomics:Open Access
  • SubjectBiochemistry & Biotechnology
  • BylineArticles whose byline prints “Dongliang Ge”